Surmodics, Inc.
SRDX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $30 | $28 | $30 | $33 |
| % Growth | 5.3% | -6.1% | -9.9% | – |
| Cost of Goods Sold | $9 | $8 | $7 | $9 |
| Gross Profit | $21 | $20 | $22 | $25 |
| % Margin | 71% | 72.1% | 75.2% | 73.9% |
| R&D Expenses | $3 | $3 | $3 | $3 |
| G&A Expenses | $0 | $15 | $0 | $15 |
| SG&A Expenses | $18 | $15 | $15 | $15 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $5 | $6 | $7 | $8 |
| Operating Expenses | $26 | $24 | $25 | $25 |
| Operating Income | -$5 | -$4 | -$2 | -$1 |
| % Margin | -17.7% | -14.3% | -8.3% | -1.8% |
| Other Income/Exp. Net | -$1 | -$1 | -$0 | -$1 |
| Pre-Tax Income | -$6 | -$5 | -$3 | -$1 |
| Tax Expense | -$1 | $1 | $1 | $2 |
| Net Income | -$5 | -$5 | -$4 | -$3 |
| % Margin | -18% | -18.5% | -12.2% | -10.4% |
| EPS | -0.37 | -0.36 | -0.26 | -0.24 |
| % Growth | -2.8% | -38.5% | -8.3% | – |
| EPS Diluted | -0.37 | -0.36 | -0.26 | -0.24 |
| Weighted Avg Shares Out | 14 | 14 | 14 | 14 |
| Weighted Avg Shares Out Dil | 14 | 14 | 14 | 14 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $2 | $2 | $2 | $2 |
| EBITDA | -$5 | -$4 | $0 | $1 |
| % Margin | -17.7% | -14.3% | 0.1% | 3% |